Semaglutide is recognized for its superior efficacy in reducing the risk of cardiovascular events, making it an attractive option for those concerned about heart health
The FDA (US), TGA (Australia), MHRA (UK), and EMA (EU) have all issued warnings about melanotan products
Large clinical trials such as the STEP 1 trial demonstrated no increased thyroid cancer incidence over 68 weeks
Post-void residual volume measurement may be arranged in primary care or via referral depending on local pathways
Sterility Concerns: Compounded substances from unregulated sources may not be manufactured under sterile conditions, increasing the risk of contamination
For patients wanting steady, medically supported fat reduction with measurable progress, Aqualyx often wins out